---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-103160"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T02:01:43.673848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics enters global supply and development pact with Medline for PermaFusion platform

## Summary
- Turn grants Medline exclusive worldwide license to use Turn's 510(k) clearance for wound-care field-of-use.
- Medline to lead global commercialization across 100+ countries; Turn provides formulation expertise, IP, and clinical development.
- Initial term of three years with automatic one-year renewals; exclusivity subject to undisclosed volume thresholds.
- Parties to collaborate on line extensions (foams, films, hydrogels, ointments, dressings) incorporating PermaFusion technology.
- Public announcement required within 72 hours of October 23, 2025 effective date.

## SEC filing metadata
- accession: 0001104659-25-103160
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000110465925103160/0001104659-25-103160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000110465925103160/tm2529649d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-103160
- JSON: https://secwatch.observer/filing/0001104659-25-103160.json
- Plain text: https://secwatch.observer/filing/0001104659-25-103160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.